Showing results (191-200 of 223) with videos related to
Sort By:
Pageof 23
Surgery Open Science|February 6, 2024
Surgical and local control outcomes after sequential short-course radiation therapy and chemotherapy for rectal cancerI-Chia Liu, Susan Gearhart, Suqi Ke, et al.Cancer Research Communications|October 29, 2024
SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in TumorsTheron Palmer, Michael D Kessler, Xiaoshan M Shao, et al.Hepatology (Baltimore, Md.)|December 3, 2024
Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1- mutant cholangiocarcinomaDaniel J Zabransky, Emma Kartalia, Jae W Lee, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activityNilofer S Azad, Edwin M Posadas, Virginia E Kwitkowski, et al.The Lancet. Oncology|August 2, 2021
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket studyMilind Javle, Mitesh J Borad, Nilofer S Azad, et al.Gynecologic Oncology|January 23, 2017
A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancersKim A Reiss, Joseph M Herman, Deborah Armstrong, et al.International Journal of Surgical Oncology|July 26, 2012
Clinicopathologic Comparison of High-Dose-Rate Endorectal Brachytherapy versus Conventional Chemoradiotherapy in the Neoadjuvant Setting for Resectable Stages II and III Low Rectal CancerJessica A Smith, Aaron T Wild, Aatur Singhi, et al.Oncotarget|March 4, 2014
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancersHuili Li, Katherine B Chiappinelli, Angela A Guzzetta, et al.The Oncologist|March 19, 2017
Academic Cancer Center Phase I Program DevelopmentArthur E Frankel, Keith T Flaherty, George J Weiner, et al.JCI Insight|December 8, 2023
CD4 T cell-activating neoantigens enhance personalized cancer vaccine efficacyAmanda L Huff, Gabriella Longway, Jacob T Mitchell, et al.Pageof 23